Opdivo (nivolumab) - Ono Pharmaceutical, BMS
Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Oct 20, 2026 - P1 | N=18 | Recruiting | Sponsor: Vanderbilt-Ingram Cancer Center | Not yet recruiting ➔ Recruiting 
Enrollment open • Head and Neck Cancer • Oncology • Oral Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck
http://clinicaltrials.gov/ct2/show/NCT07741565
 
Oct 20, 2026
 
Prev Next